Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2022 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Feb 4, 2022
Slide 1: Investor Presentation Q3FY22 February 4, 2022
Investor Presentation Q3FY22 February 4, 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q3FY22 and 9MFY22
Key Highlights of Q3FY22 and 9MFY22 • Revenue from Operations grew by 13.0% YoY during the quarter, with EBITDA margin at 19.0% and Net Profit growth of 16.6% YoY • India Business: Company’s secondary sales in Q3FY22 registered growth of 16.0% YoY compared to IPM growth of 10.4% YoY (Source: IQVIA d
Slide 4: Key Financial Highlights – Q3FY22 (Consolidated)
Key Financial Highlights – Q3FY22 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 18,156 15,140 26,190 23,181 Q3FY21 Q3FY22 International sales 7,738 YoY: (0.4)% 7,709 Q3FY21 Q3FY22 Q3FY21 Q3FY22
Slide 5: Key Financial Highlights – Q3FY22 (Consolidated)
Key Financial Highlights – Q3FY22 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,223 5,291 14,304 4,985 61.7% 61.9% 22.8% 19.0% Q3FY21 Q3FY22 Q3FY21 Q3FY22 PBT (before Minority Interest) PAT (after Minority Interest) 5,257 5,434 4,510 4,639 Q3FY21 Q3FY22
Slide 6: Key Financial Highlights – 9MFY22 (Consolidated)
Key Financial Highlights – 9MFY22 (Consolidated) All figures in ₹ mn Particulars (₹ mn) 9MFY22 9MFY21 YoY growth Revenue from Operations 81,503 66,729 22.1% Gross Profit 50,014 41,174 21.5% Gross Profit margin 61.4% 61.7% EBITDA 17,157 16,513 3.9% EBITDA margin 21.1% 24.7% PBT 16,016 15,839 1.1% PBT
Slide 7: India Business
India Business India Business: Q3FY22 Sales of ₹ 18,156 million (19.9% YoY growth) • India sales contributed 70.2% to total sales in Q3FY22 • In 9MFY22, the Company’s secondary sales grew by 31.7% YoY compared to IPM growth of 21.1% YoY (Source: IQVIA data) • Growth was mainly led by acute therapies
Slide 8: Secondary Sales Performance
Secondary Sales Performance Robust growth across all the major therapeutic segments in 9MFY22 +1 Acute Therapies Market rank 1 3 3 3 40.0% 41.5% 33.8% 25.9% 24.4% 21.3% 20.3% 19.0% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growth YoY1,2 Indian phar
Slide 9: US Business
US Business US Business: Q3FY22 Sales of ₹ 5,731 million (YoY decline of 6.9%) • US sales contributed 22.2% to total sales in Q3FY22 • YoY decline was mainly on account of significant pricing pressure on the base business which was partially offset by new product launches • In 9MFY22, the Company fi
Slide 10: US Business – Update on US FDA inspections
US Business Update on US FDA inspections Manufacturing Capability Last inspection Status post last inspection Facility Bioequivalence Taloja (India) July 2021 Successfully closed inspection without any observations Centre Received 2 observations. Already sent a detail response to the St. Louis (US)
Slide 11: Other International Business
Other International Business Other International Business: Q3FY22 Sales of ₹ 1,978 million (25.0% YoY growth) • Other International Market sales contributed 7.6% to total sales in Q3FY22 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets lik
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 31, 2021 Non-Institution, 23.53% Promoter & Promoter Group, 57.13% Institution, 19.34% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 13: Thank You
Thank You For further information or queries, please contact Gagan Borana Investor Relations Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com